Digital therapeutics for chronic disease management without medication

Patients with chronic conditions need affordable, accessible behavioral interventions to manage symptoms and improve outcomes. Digital therapeutics can reduce reliance on expensive drugs with significant side effects.

YC GraveyardJun 1, 2017ToolMedicine & HealthSource

FL score

out of 100

Verdict

BUILD

high confidence

Competition

competitors found, emerging market, funded players

Trend

1 community mentions

An AI-driven digital therapeutic for specific chronic conditions, focusing on non-medication behavioral interventions for self-pay or B2B2C, leveraging a now-mature market.

The pain

Patients with chronic conditions face high costs, significant side effects, and long-term dependence on medications, leading to a strong desire for effective, non-pharmacological alternatives.

The gap

While funded competitors exist, specific user frustrations around mandatory medication enrollment (Omada), complex plan options (Noom), and a lack of transparent, non-prescription pricing for purely behavioral DTx create a niche for a focused, AI-driven, and transparent self-pay/B2B2C solution for specific conditions.

Build angle

Build an AI-driven personalized coaching app focusing on one specific chronic condition (e.g., hypertension, anxiety) with a proven behavioral protocol, targeting self-pay or B2B2C partners to avoid immediate FDA approval, and using no-code for a rapid MVP.

Strengths

High market pain and clear demand for non-medication alternatives.
Rapidly growing digital therapeutics market with significant investor interest.
Clear payment signals from competitors and B2B2C opportunities.
Solo builder MVP is feasible using AI and no-code tools for a narrow focus.
Previous market inhibitors (regulatory, maturity) have improved significantly since the YC failure.

Risks

High competition from well-funded, established players like Omada and Noom.
Building credibility and trust for a digital therapeutic without immediate FDA approval or extensive clinical validation.
Potential for low user adherence to digital behavioral interventions.
Challenging B2B2C sales cycle for a solo founder without a strong track record.
The 'non-medication' angle might exclude a large segment of users who need integrated care.

Next steps

Conduct in-depth qualitative interviews with chronic disease patients to validate specific unmet needs and willingness to pay for a non-medication, behavioral intervention.
Identify the single most underserved chronic condition and associated behavioral protocol for the initial MVP.
Develop a clickable prototype or basic AI chatbot to test user engagement and perceived value for the narrowest wedge solution.
Explore potential early partners (e.g., small employers, niche health coaches) for a B2B2C pilot program.

Fly Labs Method

Is the pain real, is there a gap, is it the right time, can one person build it.

Problem clarity: 25
Solution gap: 14
Willingness to pay: 17
Buildability: 12

The problem of chronic disease management without medication is real and severe, with a clear willingness to pay in a rapidly growing market. However, significant competition from well-funded players means a solo builder must identify a very narrow, underserved niche, and the path to differentiate without FDA approval adds complexity.

Value Equation

Dream outcome and how likely it feels, against the time and effort it costs.

This idea benefits from significant market pain and strong growth, but faces a competitive landscape requiring clear differentiation and robust go-to-market strategy.

One-Person Business

Curiosity pull, identity fit, and a path from free value to paid for a solo creator.

The idea has strong problem clarity and monetization potential, but requires significant domain expertise or collaboration, and complex audience reach for a solo builder.

Viral Frameworks

Hook strength, shareability, and how cheaply it can be tested.

This idea has a clear value proposition and identifiable audience, with viable business models and good validation readiness, but faces risks in efficacy assumptions and distribution for a solo founder.

Builder Lens

Evidence the problem exists, timing, defensibility, and a model that fits on a napkin.

The market is now much more receptive to digital therapeutics, addressing previous failure points, but requires a highly focused initial offering.

Why this verdict

The idea addresses a significant and growing problem in a market that has matured substantially since previous failures. The willingness to pay is evident, and a solo builder can technically create an MVP. However, the presence of well-funded incumbents means that simply 'being better' won't cut it. The solo builder must validate a truly underserved, desperate niche that existing solutions fail to address, especially concerning their 'non-medication' and transparent pricing angle. Building credibility and effectively reaching users (B2B2C or self-pay) against strong competition requires initial validation of the specific gap and the efficacy of the proposed behavioral interventions.

Five lenses, one composite. How scoring works

The angle

This weekend

Conduct in-depth qualitative interviews with chronic disease patients to validate specific unmet needs and willingness to pay for a non-medication, behavioral intervention.
Identify the single most underserved chronic condition and associated behavioral protocol for the initial MVP.
Develop a clickable prototype or basic AI chatbot to test user engagement and perceived value for the narrowest wedge solution.
Explore potential early partners (e.g., small employers, niche health coaches) for a B2B2C pilot program.

Who is already there, emerging market

Omada HealthFundedVisit
Omada Health offers virtual care programs rooted in evidence, combining human-led clinical care with technology to help people manage chronic conditions like obesity, prediabetes, diabetes, hypertension, and musculoskeletal conditions.
Pricing: Pricing depends on the selected program and individual health plan coverage; Prevention, Diabetes, and Hypertension programs are often fully covered through employers or health plans, while Joint & Muscle Health may incur out-of-pocket costs.
NoomFundedVisit
Noom provides a digital health platform that combines psychology, personalized nutrition, and coaching to promote sustainable weight loss and behavior change, expanding into chronic disease management and mental health.
Pricing: Noom Weight costs $70 for one month or $17.42/month on an annual plan. Noom Med programs range from $69-$99/month for telehealth (medication not included) to $199/month (Microdose GLP-1Rx) or $279/month (Full-Dose GLP-1Rx) including compounded medication.
Akili InteractiveFundedVisit
Akili Interactive develops prescription digital medicines, delivered through high-quality action video game experiences, to treat cognitive dysfunction and brain-related conditions, with EndeavorRx™ for pediatric ADHD as its flagship product.
Pricing: Pricing information not publicly available as it is a prescription-based treatment.
Click TherapeuticsFundedVisit
Click Therapeutics offers prescription digital therapeutics and software-enhanced drug therapies to treat a wide range of conditions, including major depressive disorder, schizophrenia, opioid use disorder, and insomnia, as well as cardiometabolic diseases.
Pricing: Pricing information not publicly available as it is a prescription-based treatment.
Livongo (acquired by Teladoc Health)FundedVisit
Livongo (acquired by Teladoc Health) provided smart devices and a mobile app for diabetes management, blood pressure monitoring, and weight management, offering personalized tips and recommendations.
Pricing: Pricing information not publicly available, as the company was acquired by Teladoc Health.
Better Therapeutics (assets acquired by Click Therapeutics)Visit
Better Therapeutics developed prescription digital therapeutics (PDT) utilizing cognitive behavioral therapy delivered via mobile apps for cardiometabolic diseases, primarily type 2 diabetes. Their assets were recently acquired by Click Therapeutics.
Pricing: The Wholesale Acquisition Cost (WAC) for their AspyreRx product was $750.00 for a 90-day script. They also planned to offer a discounted cash-pay option.

Funded players

What they charge

The pricing landscape for digital therapeutics varies significantly. Some solutions, especially those offered through employers or health plans, may be fully covered with no direct cost to the patient. Others, like Noom, offer subscription-based models for individual consumers with monthly or annual plans, ranging from approximately $17 to $279 per month depending on the program and inclusion of medication. Prescription digital therapeutics, such as those from Akili Interactive and formerly Better Therapeutics, have a Wholesale Acquisition Cost (WAC) or are covered through insurance, though specific patient costs may vary. There is a trend towards enterprise pricing where companies partner with employers and health plans. Free tiers are generally not prevalent for comprehensive chronic disease management digital therapeutics, which often involve personalized coaching and clinically validated interventions.

What people say, 1 mentions

A different pathway..
r/Entrepreneur

r/r/Entrepreneur

Digital therapeutics for chronic disease management without medication

Preventive and restorative tooth care alternatives to root canal

Fertility tracking and ovulation prediction through accessible testing

Asynchronous telemedicine for chronic dermatology conditions